(NASDAQ: AZN) ASTRAZENECA's forecast annual revenue growth rate of 7.37% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 1.93%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.18%.
ASTRAZENECA's revenue in 2022 is $41,487,000,000.On average, 3 Wall Street analysts forecast AZN's revenue for 2022 to be $68,224,361,285,974, with the lowest AZN revenue forecast at $67,688,666,851,855, and the highest AZN revenue forecast at $68,689,579,681,445. On average, 3 Wall Street analysts forecast AZN's revenue for 2023 to be $72,541,956,815,278, with the lowest AZN revenue forecast at $71,570,070,457,747, and the highest AZN revenue forecast at $73,467,931,332,305.
In 2024, AZN is forecast to generate $79,563,933,593,098 in revenue, with the lowest revenue forecast at $76,026,425,662,406 and the highest revenue forecast at $83,350,008,773,675.